Pharmacological treatment of primary membranous nephropathy in 2016

被引：43

作者：

van de Logt, Anne-Els ^{[1
]}

Hofstra, Julia M. ^{[1
]}

Wetzels, Jack F. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Dept Nephrol, Radboud Inst Hlth Sci, Med Ctr, Nijmegen, Netherlands

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 11期

关键词：

Primary membranous nephropathy (MN); anti-PLA2R antibodies (aPLA2R); nephrotic syndrome; cyclophosphamide; mycophenolic acid (MMF); calcineurin inhibitors (CNIs); rituximab; ACTH; RANDOMIZED CONTROLLED-TRIAL; COMPARING METHYLPREDNISOLONE PLUS; RECEPTOR ANTIBODY TITER; NEPHROTIC SYNDROME; CYCLOSPORINE-A; ADRENOCORTICOTROPIC HORMONE; MYCOPHENOLATE-MOFETIL; RENAL-INSUFFICIENCY; TREATMENT STRATEGY; IMMUNOSUPPRESSIVE THERAPY;

D O I：

10.1080/17512433.2016.1225497

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Therapy in patients with primary membranous nephropathy is debated. The discovery of anti-PLA2R antibodies provides opportunities for new treatment strategies. Areas covered: The PubMed database and Cochrane library were searched for full-text articles published in English before March 2016. The search terms included 'Glomerulonephritis, Membranous' [MESH], 'membranous glomerulonephritis' [tiab] and, 'idiopathic membranous nephropathy' [tiab] and 'membranous nephropathy' [tiab], in combination with 'Therapeutics' [MESH], 'therapeutic*'[tiab], 'immunosuppression' [MESH] and 'immunosuppression' [tiab]. All randomized trials were included, cohort trials were included dependent of study design and sufficient number of patients. Expert commentary: With the current available immunosuppressive therapies less than 10% of patients will progress to end stage renal disease. Various treatment options are available and can be used adapted to the clinical characteristics of the patient. Treatment in patients with membranous nephropathy can be individualized using measurement of anti-PLA2R antibodies.

引用

页码：1463 / 1478

页数：16

共 90 条

[1] Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome [J].

Alexopoulos, Efstathios ;

Papagianni, Aikaterini ;

Tsamelashvili, Mzia ;

Leontsini, Maria ;

Memmos, Dimitrios .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (11) :3127-3132

[2] Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].

Appel, Gerald B. ;

Contreras, Gabriel ;

Dooley, Mary Anne ;

Ginzler, Ellen M. ;

Isenberg, David ;

Jayne, David ;

Li, Lei-Shi ;

Mysler, Eduardo ;

Sanchez-Guerrero, Jorge ;

Solomons, Neil ;

Wofsy, David .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112

[3] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].

Baigent, Colin ;

Landray, Martin J. ;

Reith, Christina ;

Emberson, Jonathan ;

Wheeler, David C. ;

Tomson, Charles ;

Wanner, Christoph ;

Krane, Vera ;

Cass, Alan ;

Craig, Jonathan ;

Neal, Bruce ;

Jiang, Lixin ;

Hooi, Lai Seong ;

Levin, Adeera ;

Agodoa, Lawrence ;

Gaziano, Mike ;

Kasiske, Bertram ;

Walker, Robert ;

Massy, Ziad A. ;

Feldt-Rasmussen, Bo ;

Krairittichai, Udom ;

Ophascharoensuk, Vuddidhej ;

Fellstrom, Bengt ;

Holdaas, Hallvard ;

Tesar, Vladimir ;

Wiecek, Andrzej ;

Grobbee, Diederick ;

de Zeeuw, Dick ;

Gronhagen-Riska, Carola ;

Dasgupta, Tanaji ;

Lewis, David ;

Herrington, William ;

Mafham, Marion ;

Majoni, William ;

Wallendszus, Karl ;

Grimm, Richard ;

Pedersen, Terje ;

Tobert, Jonathan ;

Armitage, Jane ;

Baxter, Alex ;

Bray, Christopher ;

Chen, Yiping ;

Chen, Zhengming ;

Hill, Michael ;

Knott, Carol ;

Parish, Sarah ;

Simpson, David ;

Sleight, Peter ;

Young, Alan ;

Collins, Rory .

LANCET, 2011, 377 (9784) :2181-2192

[4] Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil:: results of a pilot study [J].

Ballarin, Jose ;

Poveda, Rafael ;

Ara, Jordi ;

Perez, Laurea ;

Calero, Francesca ;

Grinyo, Josep M. ;

Romero, Ramon .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (11) :3196-3201

[5] Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis [J].

Barbour, Sean J. ;

Greenwald, Allen ;

Djurdjev, Ognjenka ;

Levin, Adeera ;

Hladunewich, Michelle A. ;

Nachman, Patrick H. ;

Hogan, Susan L. ;

Cattran, Daniel C. ;

Reich, Heather N. .

KIDNEY INTERNATIONAL, 2012, 81 (02) :190-195

[6] Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy [J].

Bech, Anneke P. ;

Hofstra, Julia M. ;

Brenchley, Paul E. ;

Wetzels, Jack F. M. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (08) :1386-1392

[7] Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy [J].

Beck, Laurence H., Jr. ;

Fervenza, Fernando C. ;

Beck, David M. ;

Bonegio, Ramon G. B. ;

Malik, Fahim A. ;

Erickson, Stephen B. ;

Cosio, Fernando G. ;

Cattran, Daniel C. ;

Salant, David J. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (08) :1543-1550

[8] M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy. [J].

Beck, Laurence H., Jr. ;

Bonegio, Ramon G. B. ;

Lambeau, Gerard ;

Beck, David M. ;

Powell, David W. ;

Cummins, Timothy D. ;

Klein, Jon B. ;

Salant, David J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01) :11-21

[9] Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy [J].

Berg, AL ;

Nilsson-Ehle, P ;

Arnadottir, M .

KIDNEY INTERNATIONAL, 1999, 56 (04) :1534-1543

[10] ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses [J].

Berg, AL ;

Arnadottir, M .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1305-1307

← 1 2 3 4 5 6 7 8 9 →